On Tuesday, Shares of Amgen, Inc. (NASDAQ:AMGN), lost -2.79% to $159.01.
Amgen, declared the publication of primary results from the Phase 3 OPTiM study in the Journal of Clinical Oncology (JCO). The data published in JCO, which were formerly presented at the Annual Meetings of the American Society of Clinical Oncology (ASCO) in 2013 and 2014, demonstrated a significantly higher durable response rate (DRR) in patients with unresected stage IIIB, IIIC or IV metastatic melanoma receiving the investigational oncolytic immunotherapy talimogene laherparepvec contrast to those who received granulocyte-macrophage colony-stimulating factor (GM-CSF). Results showed that the primary endpoint of DRR was met, however the secondary endpoint of overall survival (OS) was not met, although there was a strong trend in favor of talimogene laherparepvec.
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine.
Shares of Praxair, Inc. (NYSE:PX), declined -0.28% to $ 121.67, during its last trading session.
Praxair, is notifying packaged industrial, specialty, medical gas and bulk gas customers in the United States, Canada and Puerto Rico of price enhances effective June 1, 2015, or as contracts permit, as follows:
- Up to 15% for nitrogen, oxygen and carbon dioxide
- Up to 20% for argon and hydrogen
- Up to 15% for facility fees or cylinder rental rates
- Up to 5% on hardgoods.
Price adjustments may be higher or lower in accordance with individual contract provisions.
These adjustments are in response to rising operational costs for all products and will support capacity expansion and infrastructure reinvestment.
Praxair, produces, sells, and distributes atmospheric, process, and specialty gases, in addition to surface coatings in North America, Europe, South America, and Asia.
At the end of Tuesday’s trade, Shares of Abengoa Yield PLC (NASDAQ:ABY), lost 0.03% to $ 38.41.
Abengoa Yield, declared that its board of directors accepted the resignation as CEO of Santiago Seage due to his appointment as CEO of Abengoa, at the meeting held on May 18, 2015.
During that meeting, the board of directors unanimously approved the appointment of Javier Garoz as the new CEO with immediate effect. Javier Garoz was until now CEO of Abengoa Bioenergy and is a director of Abengoa Yield.
Abengoa Yield plc owns a portfolio of renewable energy, conventional power, and electric transmission line contracted assets in North America, South America, and Europe.
Finally, NeoPhotonics Corp (NYSE:NPTN), ended its last trade with 6.23% gain, and closed at $ 7.84.
NeoPhotonics, declared the pricing of a follow-on public offering of 5,971,034 shares of its common stock at a price to the public of $7.25 per share. In addition, NeoPhotonics has granted the underwriters a 30-day option to purchase up to an additional 895,655 shares of common stock. The offering is predictable to close on or about May 27, 2015, subject to customary closing conditions.
Needham & Company, LLC is acting as sole book-running manager for the offering. Craig-Hallum Capital Group LLC and B. Riley & Co. are acting as co-managers.
NeoPhotonics Corporation designs and manufactures hybrid photonic integrated optoelectronic modules and subsystems for bandwidth-intensive, high-speed communications networks.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
